This proposal is for 5 years of renewed institutional T32 NRSA support for the NIH/NIDA Drug Dependence Epidemiology Training Program (DDETP) located within Michigan State University College of Human Medicine Department of Epidemiology. DDETP founder/training program director is Professor James C. (Jim) Anthony, whose NIDA K05 Senior Scientist work between 2003 and 2010 included creation of the MSU DDETP, based upon his model for a successful DDETP at Johns Hopkins University (1990-2003), for which he received three mentoring awards. Also leading the program is Epidemiology Professor Naomi Breslau, and there is an interdisciplinary MSU faculty who represent epidemiology/biostatistics, quantitative methodology generally, clinical sciences/therapeutics, behavioral genetics, preclinical/clinical pharmacology, and allied fields (e.g., sociology, social work, family therapy). The main DDETP goal is to increase the number and quality of quantitatively adept epidemiologists and researchers in allied fields whose career commitment is toward NIDA's mission to prevent and control drug dependence syndromes and related suspected hazards of psychoactive drug use. The proposed 3 NIDA predoctoral trainees first complete 2-3 years of coursework with research apprenticeships, pass qualifying exams to establish candidacy for the PhD, and then complete 2-3 years of research before final defense of a monograph-length dissertation representing significant contributions of new scientific evidence that requires statistical estimation or formal hypothesis-testing in the NIDA epidemiology research context. The proposed 3 postdoctoral trainees at Levels 0, 3, &7 complete an individualized program of postgraduate research training in drug dependence epidemiology, of 1-3 years duration (mostly 1-2 years), with a greater balance of time in NIDA research. Both types of trainees complete required integrity and ethics training, and work to assemble a portfolio of first-authored and co-authored articles in journals of the field, drafts of their own investigator-initiated NIDA grant award applications, and K-type career development plans, when appropriate. The program plan is designed to meet six challenges: (1) enhancing diversity outreach, (2) greater integration with MSU's new NIH clinical translational research and training initiatives, including HIV/AIDS research, (3) new educational modules on project management and on non-academic career paths toward health science and federal agency administration, small business and industry research (e.g., NIDA SBIR &STTR), (4) use of NIH and NIDA online career tracking programs, as well as online surveys to assess the mentoring process, (5) forging new solutions to a recently appreciated 'drift away'process that now detracts from post-program success in a competitive research funding environment, and (6) cultivation of a new generation of the program's Primary Advising Faculty (PAF) members in order to promote the success of the program during the proposed renewal award period and beyond.
Epidemiology and biostatistics are two of the most basic sciences for public health practice and program evaluation, helping us make unique discoveries about the causal determinants of population-level incidence rates and working toward discovery of individual-level 'causes of cases'as can be identified in community field studies and in clinicl and public health practice settings, often in collaboration with scientists from allied fields. Whe discoveries of a clinical translational character provoke change in clinical or public health practices, large sample evaluation and the epidemiology/biostatistics research approach often is required (Phase III effectiveness research, Phase IV surveillance, etc). Helping to foster success of the NIH/NIDA research mission, this NRSA T32 research training program seeks to increase the number and quality of quantitatively adept epidemiologists and researchers in allied fields whose career commitment is toward NIDA's mission to prevent and control drug dependence syndromes and related hazards of psychoactive drug use.
|Parker, Maria A; Anthony, James C (2018) Population-level predictions from cannabis risk perceptions to active cannabis use prevalence in the United States, 1991-2014. Addict Behav 82:101-104|
|Cheng, Hui G; Anthony, James C (2018) Male-female differences in the onset of heavy drinking episode soon after first full drink in contemporary United States: From early adolescence to young adulthood. Drug Alcohol Depend 190:159-165|
|Parker, Maria A; Lopez-Quintero, Catalina; Anthony, James C (2018) Young, American Indian or Alaskan Native, and born in the USA: at excess risk of starting extra-medical prescription pain reliever use? PeerJ 6:e5713|
|Parker, Maria A; Anthony, James C (2018) Underage drinking, alcohol dependence, and young people starting to use prescription pain relievers extra-medically: A zero-inflated Poisson regression model. Exp Clin Psychopharmacol :|
|Cheng, Hui G; Lopez-Quintero, Catalina; Anthony, James C (2018) Age of onset or age at assessment-that is the question: Estimating newly incident alcohol drinking and rapid transition to heavy drinking in the United States, 2002-2014. Int J Methods Psychiatr Res 27:|
|Santiago Rivera, Olga J; Havens, Jennifer R; Parker, Maria A et al. (2018) Risk of Heroin Dependence in Newly Incident Heroin Users. JAMA Psychiatry 75:863-864|
|Parker, Maria A; Anthony, James C (2018) A prospective study of newly incident cannabis use and cannabis risk perceptions: Results from the United States Monitoring the Future study, 1976-2013. Drug Alcohol Depend 187:351-357|
|Cheng, Hui G; Anthony, James C (2018) Female-male differences in alcohol dependence levels: Evidence on newly incident adolescent and young-adult drinkers in the United States, 2002-2014. Int J Methods Psychiatr Res 27:e1717|
|Leinweber, Jacob P; Cheng, Hui G; Lopez-Quintero, Catalina et al. (2017) Newly incident cannabis use in the United States, 2002-2011: a regional and state level benchmark. PeerJ 5:e3616|
|Alshaarawy, Omayma; Anthony, James C (2017) The replicability of cannabis use prevalence estimates in the United States. Int J Methods Psychiatr Res 26:|
Showing the most recent 10 out of 77 publications